February 2026 in “Colloids and Surfaces A Physicochemical and Engineering Aspects” Using molecular dynamics simulations, this study explored the uptake processes of JAK inhibitors on stratum corneum and hair follicle membranes, revealing a unique interaction mechanism in the hair follicle and offering insights into transdermal drug delivery pathways.
1 citations
,
December 2025 in “PLoS ONE” This study evaluated the real-world safety of Tepotinib for treating NSCLC with METex14 skipping mutations, confirming known adverse events and identifying new signals like deafness and taste disorder, especially highlighting early monitoring.
19 citations
,
April 2016 in “Case Reports in Dermatology” This case report highlights an instance of nilotinib-induced keratosis pilaris without alopecia or pruritus, emphasizing the need for awareness to optimize patient outcomes.
1 citations
,
July 2023 in “Canadian Journal of Health Technologies” This review discusses selumetinib for treating symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type 1 and reports no new clinical results; it provides guidance for Canadian reimbursement decisions.
June 2024 in “ESMO Gastrointestinal Oncology” The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.